Latest Articles

Publication Date
All News Scientific
GSK’s Jemperli Set for Expanded EMA Approval for Endometrial Cancer - TipRanks

GSK’s Jemperli Set for Expanded EMA Approval for Endometrial Cancer TipRanks

Published: Dec. 16, 2024, 7:45 a.m.
Read Full Article
EU recommends expanding use of GSK endometrial cancer drug - ShareCast

EU recommends expanding use of GSK endometrial cancer drug ShareCast

Published: Dec. 16, 2024, 7:35 a.m.
Read Full Article
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis Seeking Alpha

Published: Dec. 12, 2024, 8:25 p.m.
Read Full Article
Integrating Psychosocial Support and Quality of Life into Endometrial Cancer Pathways - Journal of Clinical Pathways

Integrating Psychosocial Support and Quality of Life into Endometrial Cancer Pathways Journal of Clinical Pathways

Published: Dec. 12, 2024, 4:25 p.m.
Read Full Article
Endometrial Cancer Market Diagnosing and Treating a Growing - openPR

Endometrial Cancer Market Diagnosing and Treating a Growing openPR

Published: Dec. 11, 2024, 10:11 a.m.
Read Full Article
Early Recurrence After Surgery in FIGO 2023 Stage I-III Endometrial Cancer: Characteristics and risk factors - Frontiers

Early Recurrence After Surgery in FIGO 2023 Stage I-III Endometrial Cancer: Characteristics and risk factors Frontiers

Published: Dec. 10, 2024, 4:36 p.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - BioSpace

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer BioSpace

Published: Dec. 10, 2024, 12:23 p.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - Yahoo Finance

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer Yahoo Finance

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan

IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer StockTitan

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!